INMB
INmune Bio Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.
Market Cap: 228 Million
Primary Exchange: NASDAQ
Website: inmunebio.com
Shares Outstanding: 18 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.0907887880762497
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 789 trading days
From: 2021-09-07 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|